Characterization of Non-Monotonic Relationships between Tumor Mutational Burden and Clinical Outcomes

被引:0
|
作者
Anaya, Jordan [1 ]
Kung, Julia [2 ]
Baras, Alexander S. [1 ,3 ,4 ]
机构
[1] Johns Hopkins Univ, Dept Pathol, Sch Med, CRB II 152,1550 Orleans St, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Biomed Informat & Data Sci, Sch Med, Baltimore, MD USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
[4] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
来源
CANCER RESEARCH COMMUNICATIONS | 2024年 / 4卷 / 07期
关键词
CTLA-4; BLOCKADE; LANDSCAPE; MODELS;
D O I
10.1158/2767-9764.CRC-24-0061
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Potential clinical biomarkers are often assessed with Cox regressions or their ability to differentiate two groups of patients based on a single cutoff. However, both of these approaches assume a monotonic relationship between the potential biomarker and survival. Tumor mutational burden (TMB) is currently being studied as a predictive biomarker for immunotherapy, and a single cutoff is often used to divide patients. In this study, we introduce a two-cutoff approach that allows splitting of patients when a non-monotonic relationship is present and explore the use of neural networks to model more complex relationships of TMB to outcome data. Using real-world data, we find that while in most cases the true relationship between TMB and survival appears monotonic, that is not always the case and researchers should be made aware of this possibility.Significance: When a non-monotonic relationship to survival is present it is not possible to divide patients by a single value of a predictor. Neural networks allow for complex transformations and can be used to correctly split patients when a non-monotonic relationship is present.
引用
收藏
页码:1667 / 1676
页数:10
相关论文
共 50 条
  • [31] Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
    Mok, T. S. K.
    Lopes, G.
    Cho, B. C.
    Kowalski, D. M.
    Kasahara, K.
    Wu, Y. -l.
    de Castro Jr, G.
    Turna, H. Z.
    Cristescu, R.
    Aurora-Garg, D.
    Loboda, A.
    Lunceford, J.
    Kobie, J.
    Ayers, M.
    Pietanza, M. C.
    Piperdi, B.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2023, 34 (04) : 377 - 388
  • [32] Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product
    Willoughby, David
    Bognar, Ernest
    Stanbery, Laura
    Nagel, Casey
    Wallraven, Gladice
    Pruthi, Aman
    Bild, Nicholas
    Stamper, Ericca
    Rao, Donald
    Walter, Adam
    Nemunaitis, John
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [33] Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types
    Sinha, Neelam
    Sinha, Sanju
    Valero, Cristina
    Scha, Alejandro A.
    Aldape, Kenneth
    Litch, Kevin
    Chan, Timothy A.
    Morris, Luc G. T.
    Ruppin, Eytan
    CANCER RESEARCH, 2022, 82 (11) : 2076 - 2083
  • [34] Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases
    Stein, Matthew K.
    Pandey, Manjari
    Xiu, Joanne
    Tae, Hongseok
    Swensen, Jeff
    Mittal, Sandeep
    Brenner, Andrew J.
    Korn, W. Michael
    Heimberger, B.
    Martin, Mike G.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 13
  • [35] Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
    Berland, Lea
    Heeke, Simon
    Humbert, Olivier
    Macocco, Adam
    Long-Mira, Elodie
    Lassalle, Sandra
    Lespinet-Fabre, Virginie
    Lalvee, Salome
    Bordone, Olivier
    Cohen, Charlotte
    Leroy, Sylvie
    Hofman, Veronique
    Hofman, Paul
    Ilie, Marius
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S71 - S80
  • [36] Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer
    Vokes, Natalie I.
    Liu, David
    Ricciuti, Biagio
    Jimenez-Aguilar, Elizabeth
    Rizvi, Hira
    Dietlein, Felix
    Xiao, Meng
    Margolis, Claire A.
    Elmarakeby, Haitham A.
    Girshman, Jeffrey
    Adeni, Anika
    Sanchez-Vega, Francisco
    Schultz, Nikolaus
    Dahlberg, Suzanne
    Zehir, Ahmet
    Janne, Pasi A.
    Nishino, Mizuki
    Umeton, Renato
    Sholl, Lynette M.
    Van Allen, Eliezer M.
    Hellmann, Matthew D.
    Awad, Mark M.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 12
  • [37] Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma
    Andrews, Miles C.
    Li, Gerald
    Graf, Ryon P.
    Fisher, Virginia A.
    Mitchell, Jerry
    Aboosaiedi, Ali
    O'Rourke, Harriet
    Shackleton, Mark
    Iddawela, Mahesh
    Oxnard, Geoffrey R.
    Huang, Richard S. P.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [38] Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma
    Andrews, Miles C.
    Li, Gerald
    Graf, Ryon P.
    Fisher, Virginia A.
    Mitchell, Jerry
    Aboosaiedi, Ali
    O'Rourke, Harriet
    Shackleton, Mark
    Iddawela, Mahesh
    Oxnard, Geoffrey R.
    Huang, Richard S. P.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [39] Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy
    Dousset, Lea
    Poizeau, Florence
    Robert, Caroline
    Mansard, Sandrine
    Mortier, Laurent
    Caumont, Charline
    Routier, Emilie
    Dupuy, Alain
    Rouanet, Jacques
    Battistella, Maxime
    Greliak, Anna
    Cappellen, David
    Galibert, Marie-Dominique
    Allayous, Clara
    Lespagnol, Alexandra
    Gerard, Emilie
    Kerneuzet, Ines
    Roy, Severine
    Dutriaux, Caroline
    Merlio, Jean-Philippe
    Vergier, Beatrice
    Schrock, Alexa B.
    Lee, Jessica
    Ali, Siraj M.
    Kammerer-Jacquet, Solene-Florence
    Lebbe, Celeste
    Beylot-Barry, Marie
    Boussemart, Lise
    JCO PRECISION ONCOLOGY, 2021, 5 : 1821 - 1829
  • [40] Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine
    Dupain, Celia
    Gutman, Tom
    Girard, Elodie
    Kamoun, Choumouss
    Marret, Gregoire
    Castel-Ajgal, Zahra
    Sablin, Marie-Paule
    Neuzillet, Cindy
    Borcoman, Edith
    Hescot, Segolene
    Callens, Celine
    Trabelsi-Grati, Olfa
    Melaabi, Samia
    Vibert, Roseline
    Antonio, Samantha
    Franck, Coralie
    Galut, Michele
    Guillou, Isabelle
    Halladjian, Maral
    Allory, Yves
    Cyrta, Joanna
    Romejon, Julien
    Frouin, Eleonore
    Stoppa-Lyonnet, Dominique
    Wong, Jennifer
    Le Tourneau, Christophe
    Bieche, Ivan
    Servant, Nicolas
    Kamal, Maud
    Masliah-Planchon, Julien
    BMC BIOLOGY, 2024, 22 (01)